FZD3 Protein, Human (Cell-Free, His)

Customer Review

Based on 1 Customer Validation

FZD3 is a Wnt receptor that primarily activates the β-catenin canonical pathway, involving disheveled protein, GSK-3 kinase inhibition, nuclear β-catenin accumulation, and Wnt target gene induction. FZD3 Protein, Human (Cell-Free, His) is the recombinant human-derived FZD3 protein, expressed by E. coli Cell-free , with N-10*His labeled tag.

For research use only. We do not sell to patients.
  • Species: Human
  • Source: E. coli Cell-free
  • Storage:
    Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
  • Biological Activity
  • Technical Parameters
  • Product Properties
  • Documentation
  • Help & FAQs

Biological Activity

Description

FZD3 is a Wnt receptor that primarily activates the β-catenin canonical pathway, involving disheveled protein, GSK-3 kinase inhibition, nuclear β-catenin accumulation, and Wnt target gene induction. FZD3 Protein, Human (Cell-Free, His) is the recombinant human-derived FZD3 protein, expressed by E. coli Cell-free , with N-10*His labeled tag.

Background

FZD3, serving as a receptor for Wnt proteins, primarily engages in the beta-catenin canonical signaling pathway, orchestrating the activation of disheveled proteins, inhibition of GSK-3 kinase, nuclear accumulation of beta-catenin, and induction of Wnt target genes. A secondary signaling pathway involving PKC and calcium fluxes, observed in certain family members, raises questions about its distinct nature and potential integration with the canonical pathway, given the crucial role of PKC in Wnt-mediated GSK-3 kinase inactivation. Interactions with G-proteins are integral to both pathways. Wnt5A activation stimulates PKC activity through a G-protein-dependent mechanism. FZD3 is implicated in transducing polarity information during tissue morphogenesis and differentiated tissues, playing a critical role in controlling early axon growth and guidance processes. It is essential for the development of major fiber tracts in the central nervous system and regulates axon growth in specific populations of cranial and spinal motor neurons. Additionally, FZD3 is involved in the migration of cranial neural crest cells and contributes to the transmission of sensory information. It collaborates with FZD6 in neural tube closure and participates in establishing planar cell polarity, particularly in orienting stereocilia bundles in auditory and vestibular sensory cells. Furthermore, FZD3 promotes neurogenesis by maintaining sympathetic neuroblasts within the cell cycle through a beta-catenin-dependent mechanism. Interactions with VANGL2 further underscore its multifaceted role in cellular processes.

Technical Parameters

  • Species Human
  • Source E. coli Cell-free
  • Tag N-10*His
  • Accession
  • Gene ID
  • Molecular Construction
    • N-term
    • 10*His
    • FZD3 (H23-A666)
      Accession # Q9NPG1
    • C-term
  • Protein Length

    Full Length of Mature Protein

  • Synonyms

    FZD3; Frizzled Family Receptor 3; Frizzled Class Receptor 3; Frizzled (Drosophila) Homolog 3; Fz-3; Frizzled Homolog 3 (Drosophila); Frizzled-3; Frizzled Homolog 3; Frizzled 3, Seven Transmembrane Spanning Receptor; HFz3

  • AA Sequence

    HSLFSCEPITLRMCQDLPYNTTFMPNLLNHYDQQTAALAMEPFHPMVNLDCSRDFRPFLCALYAPICMEYGRVTLPCRRLCQRAYSECSKLMEMFGVPWPEDMECSRFPDCDEPYPRLVDLNLAGEPTEGAPVAVQRDYGFWCPRELKIDPDLGYSFLHVRDCSPPCPNMYFRREELSFARYFIGLISIICLSATLFTFLTFLIDVTRFRYPERPIIFYAVCYMMVSLIFFIGFLLEDRVACNASIPAQYKASTVTQGSHNKACTMLFMILYFFTMAGSVWWVILTITWFLAAVPKWGSEAIEKKALLFHASAWGIPGTLTIILLAMNKIEGDNISGVCFVGLYDVDALRYFVLAPLCLYVVVGVSLLLAGIISLNRVRIEIPLEKENQDKLVKFMIRIGVFSILYLVPLLVVIGCYFYEQAYRGIWETTWIQERCREYHIPCPYQVTQMSRPDLILFLMKYLMALIVGIPSVFWVGSKKTCFEWASFFHGRRKKEIVNESRQVLQEPDFAQSLLRDPNTPIIRKSRGTSTQGTSTHASSTQLAMVDDQRSKAGSIHSKVSSYHGSLHRSRDGRYTPCSYRGMEERLPHGSMSRLTDHSRHSSSHRLNEQSRHSSIRDLSNNPMTHITHGTSMNRVIEEDGTSA

  • Predicted Molecular Mass

    75.3 kDa

  • Purity

    ≥ 90%, as determined by reducing SDS-PAGE.

Product Properties

Appearance

Lyophilized powder.

Formulation

Lyophilized from a 0.22 μm filtered solution of PBS, 0.05% Brij-78, 6%trehalose, pH 7.4.

Endotoxin Level

<1 EU/μg, determined by LAL method.

Reconstitution

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH2O.

Storage & Stability

Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Shipping

Room temperature in continental US; may vary elsewhere.

Calculators

Reconstitution Calculator

Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration

Volume (to add to vial) Volume (to add to vial)
=
Mass (in vial) Mass (in vial)
÷
Desired Reconstitution Concentration Desired Reconstitution Concentration
Dilution Calculator

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

Concentration (start) Concentration (start)
×
Volume (start) Volume (start)
=
Concentration (final) Concentration (final)
×
Volume (final) Volume (final)
The Specific Activity Calculator Equation
  • Specific Activity (Unit/mg)
  • Biological Activity (ED50)

Specific Activity (Unit/mg) = 106 ÷ Biological Activity (ED50)

Specific Activity (Unit/mg) Specific Activity (Unit/mg)
Unit/mg
= 106 ÷
Biological Activity (ED50) Biological Activity (ED50)
106 ÷
ng/mL
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00